146 related articles for article (PubMed ID: 30129377)
1. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Miner PB
Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
[TBL] [Abstract][Full Text] [Related]
2. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
3. Elobixibat for the treatment of constipation.
Wong BS; Camilleri M
Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
5. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
6. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
Ikeda N; Taniguchi S; Seki M
Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
[TBL] [Abstract][Full Text] [Related]
8. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
[TBL] [Abstract][Full Text] [Related]
10. Review article: Elobixibat: a novel treatment for chronic constipation.
Khanna L; Camilleri M
Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
[TBL] [Abstract][Full Text] [Related]
11. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
[TBL] [Abstract][Full Text] [Related]
12. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs.
Taniguchi S; Yano T; Imaizumi M; Manabe N
Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.
Mosińska P; Fichna J; Storr M
World J Gastroenterol; 2015 Jun; 21(24):7436-42. PubMed ID: 26139989
[TBL] [Abstract][Full Text] [Related]
14. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
Nakajima A; Ishizaki S; Matsuda K; Kurosu S; Taniguchi S; Gillberg PG; Mattsson JP; Hasunuma T; Camilleri M
J Gastroenterol Hepatol; 2022 May; 37(5):883-890. PubMed ID: 35168298
[TBL] [Abstract][Full Text] [Related]
15. Elobixibat and its potential role in chronic idiopathic constipation.
Acosta A; Camilleri M
Therap Adv Gastroenterol; 2014 Jul; 7(4):167-75. PubMed ID: 25057297
[TBL] [Abstract][Full Text] [Related]
16. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice.
Yamauchi R; Takedatsu H; Yokoyama K; Yamauchi E; Kawashima M; Nagata T; Uchida Y; Kitaguchi T; Higashi T; Fukuda H; Tsuchiya N; Takata K; Tanaka T; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
Hepatol Int; 2021 Apr; 15(2):392-404. PubMed ID: 33398776
[TBL] [Abstract][Full Text] [Related]
17. New pharmacological treatment options for chronic constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
[TBL] [Abstract][Full Text] [Related]
18. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.
Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR
Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
Nakajima A; Taniguchi S; Kurosu S; Gillberg PG; Mattsson JP; Camilleri M
Neurogastroenterol Motil; 2019 May; 31(5):e13571. PubMed ID: 30793431
[TBL] [Abstract][Full Text] [Related]
20. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.
Chey WD; Camilleri M; Chang L; Rikner L; Graffner H
Am J Gastroenterol; 2011 Oct; 106(10):1803-12. PubMed ID: 21606974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
